Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice.
Numerous studies have demonstrated the utility of topical tacrolimus ointment in atopic dermatitis. However, there is a concern that local immunosuppression by calcineurin inhibitors may enhance dermal photocarcinogenesis and carcinogenesis. Therefore, we investigated the influence of topical tacrolimus ointment on squamous cell carcinoma formation in hairless female C3.Cg/TifBomTac immunocompetent mice exposed to solar simulated radiation (SSR). In a first experiment, mice (n = 200) had tacrolimus applied on their dorsal skin three times weekly followed by SSR (2, 4 or 6 standard erythema doses, SED) 3-4 h later. Tacrolimus did not reduce the time to tumor development and in the group receiving 4 SED it even had a protective effect (156 days vs 170 days, P = 0.008). In a second experiment, mice (n = 50) were irradiated with 6 SED three times weekly for 3 months and subsequently treated five times weekly with topical tacrolimus to mimic the use of tacrolimus on sun-damaged skin. The median time to the first skin tumor was 234 days in SSR + tacrolimus group compared with 227 days in the only SSR-irradiated group (P = 0.160). In a third experiment, mice (n = 25) had tacrolimus applied on their dorsal skin every day for 1 month, thereafter the group was irradiated with 4 SED three times weekly. The median time to the first skin tumor was 142 days in tacrolimus + SSR group compared with 156 days in the only SSR-irradiated group from experiment 1 (P = 0.363). We conclude that tacrolimus ointment does not accelerate photocarcinogenesis or induce any dermal carcinogenicity in hairless mice.
Lerche
Catharina M
CM
Department of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark. CL21@bbh.regionh.dk
Philipsen
Peter A
PA
Poulsen
Thomas
T
Wulf
Hans Christian
HC
D000287:Administration, Topical; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000503:physiopathology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000528:radiation effects*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008812:Mice, Hairless; D009381:Neoplasms, Radiation-Induced / Q000473:pathology / Q000503:physiopathology; D012867:Skin / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D012878:Skin Neoplasms / Q000473:pathology / Q000503:physiopathology; D012880:Skin Pigmentation / Q000187:drug effects / Q000528:radiation effects; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology*; D014466:Ultraviolet Rays / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D016559:Tacrolimus